Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Aggressive Dosing May Increase Cardiovascular Risk – NEJM Studies

Executive Summary

Two recently published studies may curtail aggressive elevation of hemoglobin levels with erythropoiesis-stimulating agents in anemia patients

You may also be interested in...



ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says

Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says

ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says

Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says

Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint

Results from an Amgen trial showing that anemia therapy Aranesp has a neutral impact on survival in cancer patients receiving chemotherapy could assuage concerns over the safety profile of erythropoiesis-stimulating agents at high doses

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel